EPZ5676: Potent DOT1L Inhibitor for MLL-Rearranged Leukemia and Epigenetic Research

Executive Summary: EPZ5676, developed by APExBIO, is a potent and selective DOT1L histone methyltransferase inhibitor with an IC₅₀ of 0.8 nM and a Ki of 80 pM, exhibiting over 37,000-fold selectivity versus other methyltransferases (product documentation). It competitively occupies the S-adenosyl methionine (SAM) binding pocket of DOT1L, leading to conformational changes that inhibit H3K79 methylation. EPZ5676 induces cytotoxicity in acute leukemia cell lines harboring MLL translocations and demonstrates complete tumor regression in MV4-11 xenograft rat models without significant toxicity (Kim et al. 2018). The compound is highly soluble in DMSO and ethanol, but insoluble in water, and is recommended for storage at -20°C. Its use streamlines histone methyltransferase inhibition assays and enables advanced study of epigenetic regulation in cancer.

Biological Rationale

DOT1L is a histone methyltransferase responsible for methylation at lysine 79 of histone H3 (H3K79). Aberrant H3K79 methylation is a hallmark of MLL-rearranged leukemias, contributing to deregulated gene expression and oncogenesis (Kim et al. 2018). Targeted inhibition of DOT1L disrupts this epigenetic modification, downregulating MLL-fusion target genes and impairing leukemia cell proliferation (internal article). While other methyltransferases are implicated in chromatin regulation, the unique role of DOT1L in certain leukemias makes it a compelling drug target. Epigenetic drugs, including DOT1L inhibitors, offer mechanistic specificity, reducing off-target effects compared to broad-acting cytotoxics. By targeting the root of aberrant gene expression, EPZ5676 enables the dissection of epigenetic regulation in both disease and normal states (internal review).

Mechanism of Action of DOT1L inhibitor EPZ-5676

EPZ5676 acts as a competitive inhibitor, occupying the S-adenosyl methionine (SAM) binding pocket of DOT1L. This binding induces a conformational change, opening a hydrophobic pocket beyond the amino acid portion of SAM, which further enhances selectivity (APExBIO). EPZ5676 prevents the methyl transfer to H3K79, leading to rapid depletion of H3K79 methylation marks in sensitive cells. The specificity of EPZ5676 is validated by over 37,000-fold selectivity against key methyltransferases, including CARM1, EHMT1/2, PRMTs, SETD7, SMYD2/3, and WHSC1/1L1. This selectivity is crucial for avoiding unintended epigenetic perturbation. In MLL-rearranged leukemia, inhibition of H3K79 methylation by EPZ5676 causes transcriptional repression of MLL-fusion oncogenes, triggering apoptosis and impaired proliferation (internal update). The compound demonstrates robust cell permeability and is suitable for both in vitro and in vivo applications.

Evidence & Benchmarks

• EPZ5676 exhibits an IC₅₀ of 0.8 nM and a Ki of 80 pM for DOT1L inhibition, demonstrating high potency (APExBIO).
• Displays over 37,000-fold selectivity versus other methyltransferases, minimizing off-target effects (APExBIO).
• Reduces H3K79 methylation and downregulates MLL-fusion target gene expression in MLL-rearranged leukemia models (Kim et al. 2018).
• Induces potent cytotoxicity in MV4-11 acute leukemia cell lines with an IC₅₀ of 3.5 nM after 4–7 days of exposure (APExBIO).
• In vivo, intravenous administration (35–70 mg/kg/day for 21 days) results in complete regression of MV4-11 xenograft tumors in nude rats, with no significant toxicity or weight loss (Kim et al. 2018).
• Solubility: ≥28.15 mg/mL in DMSO and ≥50.3 mg/mL in ethanol (ultrasonic assistance); insoluble in water (APExBIO).
• Recommended storage at -20°C, with DMSO stock solutions stable below -20°C for several months (APExBIO).

Applications, Limits & Misconceptions

EPZ5676 is primarily used in biochemical enzyme inhibition assays, histone methyltransferase inhibition studies, and cell proliferation assays involving leukemia models. Its primary indication is for MLL-rearranged leukemia research, where it enables interrogation of H3K79 methylation and downstream oncogenic effects. The compound has also been adopted for screening workflows in drug discovery and mechanistic epigenetics studies. While EPZ5676 shows exceptional specificity for DOT1L, it is not active against histone demethylases, nor does it directly modulate Wnt/β-catenin signaling as described for other epigenetic modulators like JIB-04 (Kim et al. 2018).

Common Pitfalls or Misconceptions

• EPZ5676 is not effective against histone demethylases or non-DOT1L methyltransferases; its utility is restricted to DOT1L-mediated methylation inhibition.
• The compound is insoluble in water and must be prepared in DMSO or ethanol with ultrasonic assistance for optimal dissolution.
• EPZ5676 should not be used for long-term solution storage; fresh preparations are recommended for reproducibility.
• It is not suitable for targeting Wnt/β-catenin signaling or general cancer stem cell pathways, unlike pan-selective inhibitors such as JIB-04.
• In vivo efficacy and safety have been validated in preclinical models; clinical translation should consider species differences and dosing regimens.

Workflow Integration & Parameters

For biochemical assays, EPZ5676 is typically reconstituted in DMSO to a concentration ≥28.15 mg/mL and stored at -20°C (APExBIO). In cell-based proliferation assays, an IC₅₀ of 3.5 nM is achieved in MV4-11 cells after 4–7 days of continuous exposure. For in vivo applications, intravenous administration in nude rat xenograft models is performed at 35–70 mg/kg/day for 21 days. Stock solutions in DMSO remain stable for several months when stored below -20°C. The compound integrates seamlessly into histone methyltransferase inhibition workflows, providing reproducible, high-sensitivity results (internal troubleshooting guide contrasts by emphasizing real-world protocol optimization).

This article extends the data-driven perspectives in "DOT1L inhibitor EPZ-5676 (SKU A4166): Data-Driven Best Practices" by offering new mechanistic clarity and updated benchmarks from recent literature.

Conclusion & Outlook

DOT1L inhibitor EPZ-5676 (SKU A4166) from APExBIO is a cornerstone tool for precision epigenetic studies in MLL-rearranged leukemia. Its unrivaled potency, selectivity, and translational efficacy empower researchers to dissect H3K79 methylation's biological roles and downstream transcriptional events. As epigenetic therapies advance, EPZ5676 provides a validated model for targeted histone modification inhibition. Future directions include combinatorial epigenetic drug strategies and expanded use in mechanistic cancer research (official product page).